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ARE WE JUSTIFIED IN THE DISMISSING MICROSCOPIC PYURIA OF 1 -9 WBC ΜL-1 AS 
NORMAL IN SYMPTOMATIC PATIENTS? 
Hypothesis / aims of study 
There is growing interest in chronic cystitis in the aetiology of overactive bladder (OAB). The tests used routinely to exclude 
urinary tract infection (UTI) have been discredited, catalysing a critical analysis of our assumptions. The Kass criterion used for 
diagnosing UTI is based on data from patients with acute pyelonephritis without justification for application to other symptomatic 
groups. Urinary dipsticks being calibrated to this criteria, prove particularly misleading. The detection of microscopic pyuria 
remains the best surrogate marker of infection. The literature recommends the threshold  ≥10 wbc µl
-1
 suggestive of 
pathological pyuria but there are no data to justify this. Thus pyuria in the range 1-9  wbc µl
-1
 merits scrutiny to test its 
innocence (1). There are other measures of immune activation in the urinary tract suitable as independent arbiters of the true 
pathology (2). Lactoferrin which chelates iron thereby starving microbes, is elevated in urine in patients with acute UTI. 
Urothelial cells constitutively express IL-6 and studies show rapid increases in IL-6 after the onset of infection. Urothelial cells 
when infected with microbes, signal their distress by expressing ATP. We capitalised on the immune properties of these three 
proteins to scrutinise the significance of pyuria1-9 wbc µl
-1
 and ≥10 wbc µl
-1
.
Study design, materials and methods 
A prospective observational study was conducted from February 2011 to July 2012. Patients presenting with OAB were 
recruited from incontinence clinics and clean-catch midstream urine samples obtained. Healthy control volunteers were 
recruited from hospital staff.  Light microscopy was performed on fresh urine for leucocytes and urothelial cell counts by blinded 
investigators. Aliquots of spun urine were frozen at -80°C which were analysed for Lactoferrin and IL6 by high sensitivity ELISA 
and ATP using a luciferin-luciferase assay. 
Results 
There were 75 controls (F=49 M=26; Mean age 38.1yrs sd=15.8) and 340 patients (F=314; M=26; Mean age 58.6yrs sd=16.6); 
100 patients had OAB no pyuria, 120 had OAB pyuria 1-9 wbc µl
-1
 and 120 OAB ≥ 10 wbc µl
-1
.  Pyuria 1-9 wbc µl
-1
 was clearly 
associated with inflammatory urinary tract disease. Regression analysis revealed significant associations with urinary lactoferrin 
(R= .41, t=4, p<0.001) and, IL6 (R=.42, t=3.3 p=.001). ATP reflected only pyuria ≥ 10 wbc µl
-1
.  It seems that pyuria 1-9 wbc µl
-1 
has been overlooked because of spectrum bias between the poles of zero pyuria and pyuria≥ 10 wbc µl
-1
.
Figure 1: Lactoferrin and pyuria in OAB patients 
 
 
Figure 2: IL6 and pyuria in OAB patients 
  
 
Interpretation of results 
These data support the hypothesis that symptomatic patients with a pyuria1-9 wbc µl
-1
, have evidence of an inflammatory signal 
in their urine significantly higher than that of control participants.           
 
Concluding message 
It is universally accepted that in all patients presenting with urgency and frequency the exclusion of UTI is mandatory. These 
data indicate that we need to reassess the implications of pyuria ≤10 wbc µl
-1
 in symptomatic patients as its occurrence may 
infact be an important marker of significant disease. 
 
References 
1. (1) Neurourol Urodyn 2009;28(7):754-5. 
2. (2) Eur J Clin Invest. 2008 Oct;38 Suppl 2:29-38 
 
Disclosures 
Funding: None Clinical Trial: No Subjects: HUMAN Ethics Committee: This work was conducted with approval from the 
Whittington and Moorefield’s Research Ethical Committee, London. Helsinki: Yes Informed Consent: Yes  
 
 
